Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
Memorial Sloan Kettering Cancer Center
Totus Medicines
BeOne Medicines
UNC Lineberger Comprehensive Cancer Center
Indiana University
BeOne Medicines
Context Therapeutics Inc.
Washington University School of Medicine
"Oncostar" LLC
Bayer
University of Colorado, Denver
NiKang Therapeutics, Inc.
Aktis Oncology, Inc.
Novartis
EMD Serono
Regor Pharmaceuticals Inc.
Seagen Inc.
Eli Lilly and Company
Compass Therapeutics
Pliant Therapeutics, Inc.
Eli Lilly and Company
Pfizer
City of Hope Medical Center
MOMA Therapeutics
Eli Lilly and Company
Eli Lilly and Company
Eli Lilly and Company
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Kivu Bioscience Inc.
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
AstraZeneca
BeOne Medicines
Exelixis
Incyte Corporation
Mersana Therapeutics
Cellectar Biosciences, Inc.
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Cancer Trials Ireland
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Providence Health & Services